Long-term safety follow-up of people treated with ADP cell therapy for cancer
Tracks long-term safety of people who received ADP cell therapy for cancer.
Plain-language title generated from the registry record
Registry title: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Key facts
- Where
- Seville, SpainSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received ADP adoptive cell therapy. It follows their long-term safety for up to 15 years after the last infusion.
- Sex
- All sexes can join.
- Earlier treatment
- People must have had at least one dose of ADP adoptive cell therapy. They must have finished or left an ADP-sponsored or supported study, or finished treatment through managed access to a GSK adoptive cell therapy.
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario Virgen del RocioSeville, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- USWM CT, LLC
- Trial code
- NCT03391778
- Record updated
- 11 August 2026
- Original description
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.Read full original descriptionShow less
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Inclusion: Participants who have received at least one dose of ADP adoptive cell therapy agent; Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it; Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy; Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; The investigator is responsible for review of medical history; Capable of giving signed informed consent.
Exclusion: None.